Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical
company focused on precision diagnostic radiopharmaceuticals, today
announced results from a meta-analysis study of Lymphoseek® (technetium
Tc 99m tilmanocept) Injection, a novel, receptor-targeted,
small-molecule radiopharmaceutical. The study compared Lymphoseek
performance data from ...
read more